Last reviewed · How we verify
Comparing Load and Concomitant therapy
Comparing Load and Concomitant therapy, marketed by Helwan University, is a drug with a key composition patent expiring in 2028. The primary strength of this therapy lies in its unique mechanism, which differentiates it from existing treatments. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Comparing Load and Concomitant therapy |
|---|---|
| Also known as | Clarithromycin - pantoprazole - Metronidazole - Amoxycyllin |
| Sponsor | Helwan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma (PHASE3)
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (PHASE3)
- Methods of T Cell Depletion Trial (MoTD) (PHASE2)
- A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection (PHASE4)
- LOAD VS Levofloxacine Concomitant (PHASE4)
- A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor (PHASE3)
- Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (PHASE2)
- Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |